prof. dr. B. (Bob) Wilffert

Head of Department PharmacoTherapy, -Epidemiology and -Economics

Research

Postal address:
A Deusinglaan1
Gebouw 3214, ruimte 0466
9713 AV
Groningen
Netherlands
Phone: +31 50 363 7576
  1. 2014
  2. Wilffert, B., Sven, H., Mulder, RHN., van Schaik, M., Nijenhuis, L., Grandia, AH., ... Deneer, VHM. (2014). Implementation of Pharmacogenetics in Evidence-Based Medicine: Toward Advancing Personalized Medicine: Chapter 22. . In I. S. Vizirianakis (Ed.), Handbook of personalized medicine. Advances in Nanotechnology, Drug Delivery, and Theory (pp. 953-1116). Pan Stanford Publishing.
  3. 2012
  4. Huyen, H. T. K., & Wilffert, B. (2012). Clinical Pharmacokinetics: Chapter 1. In H. T. K. Huyền, & JRBJ. Brouwers (Eds.), Handbook of Clinical Pharmacy (in two volumes): DƯỢC LÂM SÀNG NHỮNG NGUYÊN LÝ CƠ BẢN VÀ SỬ DỤNG THUỐC TRONG ĐIỀU TRỊ (pp. 13-36)
  5. 2011
  6. van Harten, P., & Wilffert, B. (2011). Bewegingsstoornissen. In AJM. Loonen, & JE. Hovens (Eds.), Handboek Functionele Psychofarmacologie (pp. 393-405). De Tijdstroom.
  7. Wilffert, B. (2011). Cardiovasculaire bijwerkingen. In AJM. Loonen, & JE. Hovens (Eds.), Handboek Functionele Psychofarmacologie (pp. 427-432). De Tijdstroom.
  8. Wilffert, B., & Loonen, A. (2011). Inleiding in lichamelijke bijwerkingen. In AJM. Loonen, & JE. Hovens (Eds.), Handboek Functionele Psychofarmacologie (pp. 390-391). De Tijdstroom.
  9. 1999
  10. Oosterhuis, B., Tamminga, W. J., Wemer, J., Wieling, J., Wilffert, B., Sakiman, E. P., ... Jonkman, J. H. G. (1999). Mephenytoin as a marker for CYP2C19 enzyme activity: influence of analytical factors on teh outcome of phenotyping. In A. R. Boobis, P. Kremers, O. Pelkonen, & K. Pithan (Eds.), Proceedings European Symposium on the prediction of drug metabolism in man: progress and problems (pp. 197 - 200). Luxembourg: Office for official publications of the european communities.

ID: 218810